Cymabay Therapeutics (CBAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2021 | 03-2021 | 12-2020 | 09-2020 | 06-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -40,773 | -17,551 | -50,986 | -35,235 | -23,814 |
| Depreciation Amortization | 765 | 360 | 528 | 468 | 3 |
| Accounts payable and accrued liabilities | 798 | 1,375 | -2,272 | -1,556 | -2,027 |
| Other Working Capital | -5,141 | -5,875 | -1,591 | -415 | -1,607 |
| Other Operating Activity | 4,576 | 1,130 | 9,596 | 6,829 | 4,988 |
| Operating Cash Flow | $-39,775 | $-20,561 | $-44,725 | $-29,909 | $-22,457 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 44,460 | 35,788 | 47,978 | 52,327 | 93,632 |
| PPE Investments | -87 | -94 | -21 | -21 | N/A |
| Investing Cash Flow | $44,373 | $35,694 | $47,957 | $52,306 | $93,632 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 106 | N/A | 92 | 7 | 7 |
| Financing Cash Flow | $106 | $N/A | $92 | $7 | $7 |
| Beginning Cash Position | 28,193 | 28,193 | 24,869 | 24,869 | 24,869 |
| End Cash Position | 32,897 | 43,326 | 28,193 | 47,273 | 96,051 |
| Net Cash Flow | $4,704 | $15,133 | $3,324 | $22,404 | $71,182 |
| Free Cash Flow | |||||
| Operating Cash Flow | -39,775 | -20,561 | -44,725 | -29,909 | -22,457 |
| Capital Expenditure | -87 | -94 | -21 | -21 | 0 |
| Free Cash Flow | -39,862 | -20,655 | -44,746 | -29,930 | -22,457 |